75 related articles for article (PubMed ID: 16394138)
1. Novel MDM2 p53-independent functions identified through RNA silencing technologies.
Zhang Z; Wang H; Li M; Rayburn E; Agrawal S; Zhang R
Ann N Y Acad Sci; 2005 Nov; 1058():205-14. PubMed ID: 16394138
[TBL] [Abstract][Full Text] [Related]
2. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
Wang H; Yu D; Agrawal S; Zhang R
Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
[TBL] [Abstract][Full Text] [Related]
3. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
Wang H; Nan L; Yu D; Agrawal S; Zhang R
Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
Wang H; Nan L; Yu D; Lindsey JR; Agrawal S; Zhang R
Mol Med; 2002 Apr; 8(4):185-99. PubMed ID: 12149568
[TBL] [Abstract][Full Text] [Related]
5. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models.
Zhang Z; Wang H; Prasad G; Li M; Yu D; Bonner JA; Agrawal S; Zhang R
Clin Cancer Res; 2004 Feb; 10(4):1263-73. PubMed ID: 14977824
[TBL] [Abstract][Full Text] [Related]
6. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy.
Zhang Z; Li M; Wang H; Agrawal S; Zhang R
Proc Natl Acad Sci U S A; 2003 Sep; 100(20):11636-41. PubMed ID: 13130078
[TBL] [Abstract][Full Text] [Related]
7. Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms.
Zhang R; Wang H; Agrawal S
Curr Cancer Drug Targets; 2005 Feb; 5(1):43-9. PubMed ID: 15720188
[TBL] [Abstract][Full Text] [Related]
8. Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms.
Wang H; Oliver P; Zhang Z; Agrawal S; Zhang R
Ann N Y Acad Sci; 2003 Dec; 1002():217-35. PubMed ID: 14751837
[TBL] [Abstract][Full Text] [Related]
9. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
Wang H; Wang S; Nan L; Yu D; Agrawal S; Zhang R
Int J Oncol; 2002 Apr; 20(4):745-52. PubMed ID: 11894120
[TBL] [Abstract][Full Text] [Related]
10. Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway.
Zhang Z; Wang H; Li M; Rayburn ER; Agrawal S; Zhang R
Oncogene; 2005 Nov; 24(48):7238-47. PubMed ID: 16170383
[TBL] [Abstract][Full Text] [Related]
11. E2F1 inhibits MDM2 expression in a p53-dependent manner.
Tian X; Chen Y; Hu W; Wu M
Cell Signal; 2011 Jan; 23(1):193-200. PubMed ID: 20837136
[TBL] [Abstract][Full Text] [Related]
12. MDM2 oncogene as a target for cancer therapy: An antisense approach.
Wang H; Zeng X; Oliver P; Le LP; Chen J; Chen L; Zhou W; Agrawal S; Zhang R
Int J Oncol; 1999 Oct; 15(4):653-60. PubMed ID: 10493945
[TBL] [Abstract][Full Text] [Related]
13. E2F1-dependent oncogenic addiction of melanoma cells to MDM2.
Verhaegen M; Checinska A; Riblett MB; Wang S; Soengas MS
Oncogene; 2012 Feb; 31(7):828-41. PubMed ID: 21743494
[TBL] [Abstract][Full Text] [Related]
14. Molecular imaging of MDM2 messenger RNA with 99mTc-labeled antisense oligonucleotides in experimental human breast cancer xenografts.
Fu P; Shen B; Zhao C; Tian G
J Nucl Med; 2010 Nov; 51(11):1805-12. PubMed ID: 20956468
[TBL] [Abstract][Full Text] [Related]
15. Chemosensitization by antisense oligonucleotides targeting MDM2.
Bianco R; Ciardiello F; Tortora G
Curr Cancer Drug Targets; 2005 Feb; 5(1):51-6. PubMed ID: 15720189
[TBL] [Abstract][Full Text] [Related]
16. Synergistic suppression of prostatic cancer cells by coexpression of both murine double minute 2 small interfering RNA and wild-type p53 gene in vitro and in vivo.
Ji K; Wang B; Shao YT; Zhang L; Liu YN; Shao C; Li XJ; Li X; Hu JD; Zhao XJ; Xu DQ; Li Y; Cai L
J Pharmacol Exp Ther; 2011 Jul; 338(1):173-83. PubMed ID: 21444629
[TBL] [Abstract][Full Text] [Related]
17. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway.
Li M; Zhang Z; Hill DL; Wang H; Zhang R
Cancer Res; 2007 Mar; 67(5):1988-96. PubMed ID: 17332326
[TBL] [Abstract][Full Text] [Related]
18. The roles of E6-AP and MDM2 in p53 regulation in human papillomavirus-positive cervical cancer cells.
Traidej M; Chen L; Yu D; Agrawal S; Chen J
Antisense Nucleic Acid Drug Dev; 2000 Feb; 10(1):17-27. PubMed ID: 10726657
[TBL] [Abstract][Full Text] [Related]
19. MDMX (MDM4), a Promising Target for p53 Reactivation Therapy and Beyond.
Marine JC; Jochemsen AG
Cold Spring Harb Perspect Med; 2016 Jul; 6(7):. PubMed ID: 27371671
[TBL] [Abstract][Full Text] [Related]
20. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
